Evidence map›Paper›PMID 29246178›Full record

ArticleMicrobiome2017

Discovery of the fourth mobile sulfonamide resistance gene.

Mohammad Razavi, Nachiket P Marathe, Michael R Gillings, Carl-Fredrik Flach, Erik Kristiansson, D G Joakim Larsson

Open access · goldAbstract read
In one paragraph

Article in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. Predicting Antibiotic Resistance inInternational journal of molecular sciences · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Sulfonamide resistance geneMicrobiology spectrum · 2026
    Article
  8. Review
  9. First national study on genomic profiling ofEnvironmental challenges (Amsterdam, Netherlands) · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genomic Characterization and Safety Assessment ofJournal of microbiology and biotechnology · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mohammad RazaviCentre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Nachiket P MaratheCentre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Michael R GillingsDepartment of Biological Sciences, Genes to Geoscience Research Centre, Macquarie University, Sydney, New South Wales, Australia.
Carl-Fredrik FlachCentre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Erik KristianssonCentre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
D G Joakim LarssonCentre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden. joakim.larsson@fysiologi.gu.se.
University of Gothenburg · SEChalmers University of Technology · SEMacquarie University · AU

Funding

Svenska Forskningsrådet Formas 942-2015-750Vetenskapsrådet 521-2013-8633Vetenskapsrådet (SE) 2015-02492
6 · The paper itself

Abstract

backgroundOver the past 75 years, human pathogens have acquired antibiotic resistance genes (ARGs), often from environmental bacteria. Integrons play a major role in the acquisition of antibiotic resistance genes. We therefore hypothesized that focused exploration of integron gene cassettes from microbial communities could be an efficient way to find novel mobile resistance genes. DNA from polluted Indian river sediments were amplified using three sets of primers targeting class 1 integrons and sequenced by long- and short-read technologies to maintain both accuracy and context.

resultsUp to 89% of identified open reading frames encode known resistance genes, or variations thereof (> 1000). We identified putative novel ARGs to aminoglycosides, beta-lactams, trimethoprim, rifampicin, and chloramphenicol, including several novel OXA variants, providing reduced susceptibility to carbapenems. One dihydropteroate synthase gene, with less than 34% amino acid identity to the three known mobile sulfonamide resistance genes (sul1-3), provided complete resistance when expressed in Escherichia coli. The mobilized gene, here named sul4, is the first mobile sulfonamide resistance gene discovered since 2003. Analyses of adjacent DNA suggest that sul4 has been decontextualized from a set of chromosomal genes involved in folate synthesis in its original host, likely within the phylum Chloroflexi. The presence of an insertion sequence common region element could provide mobility to the entire integron. Screening of 6489 metagenomic datasets revealed that sul4 is already widespread in seven countries across Asia and Europe.

conclusionsOur findings show that exploring integrons from environmental communities with a history of antibiotic exposure can provide an efficient way to find novel, mobile resistance genes. The mobilization of a fourth sulfonamide resistance gene is likely to provide expanded opportunities for sulfonamide resistance to spread, with potential impacts on both human and animal health.

Indexed as

IntegronsAminoglycosidesAnimalsAnti-Bacterial AgentsBacteriabeta-LactamsBioprospectingCross InfectionDihydropteroate SynthaseDrug Resistance, MicrobialEscherichia coliGenes, BacterialHumansIndiaMetagenomicsMicrobial ConsortiaAminoglycosidesAnti-Bacterial Agentsbeta-LactamsDihydropteroate SynthaseRNA, Ribosomal, 16SSulfonamidesBioprospectingEnvironmentEvolutionMetagenomicsPharmaceuticalResistome

Identifiers

PMID29246178
PMCPMC5732528
OpenAlexW2772983237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.